DOI record:
{
"DOI": "10.1016/j.bbadis.2021.166294",
"ISSN": [
"0925-4439"
],
"URL": "http://dx.doi.org/10.1016/j.bbadis.2021.166294",
"alternative-id": [
"S0925443921002271"
],
"article-number": "166294",
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.bbadis.2021.166294"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2021 Elsevier B.V."
}
],
"author": [
{
"affiliation": [],
"family": "Low",
"given": "Zheng Yao",
"sequence": "first"
},
{
"affiliation": [],
"family": "Yip",
"given": "Ashley Jia Wen",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Lal",
"given": "Sunil K.",
"sequence": "additional"
}
],
"container-title": "Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease",
"container-title-short": "Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2021,
10,
22
]
],
"date-time": "2021-10-22T01:41:47Z",
"timestamp": 1634866907000
},
"deposited": {
"date-parts": [
[
2023,
3,
6
]
],
"date-time": "2023-03-06T15:26:35Z",
"timestamp": 1678116395000
},
"indexed": {
"date-parts": [
[
2024,
5,
13
]
],
"date-time": "2024-05-13T21:14:52Z",
"timestamp": 1715634892014
},
"is-referenced-by-count": 30,
"issue": "2",
"issued": {
"date-parts": [
[
2022,
2
]
]
},
"journal-issue": {
"issue": "2",
"published-print": {
"date-parts": [
[
2022,
2
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
2,
1
]
],
"date-time": "2022-02-01T00:00:00Z",
"timestamp": 1643673600000
}
},
{
"URL": "http://www.elsevier.com/open-access/userlicense/1.0/",
"content-version": "vor",
"delay-in-days": 365,
"start": {
"date-parts": [
[
2023,
2,
1
]
],
"date-time": "2023-02-01T00:00:00Z",
"timestamp": 1675209600000
}
},
{
"URL": "https://doi.org/10.15223/policy-017",
"content-version": "stm-asf",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
2,
1
]
],
"date-time": "2022-02-01T00:00:00Z",
"timestamp": 1643673600000
}
},
{
"URL": "https://doi.org/10.15223/policy-037",
"content-version": "stm-asf",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
2,
1
]
],
"date-time": "2022-02-01T00:00:00Z",
"timestamp": 1643673600000
}
},
{
"URL": "https://doi.org/10.15223/policy-012",
"content-version": "stm-asf",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
2,
1
]
],
"date-time": "2022-02-01T00:00:00Z",
"timestamp": 1643673600000
}
},
{
"URL": "https://doi.org/10.15223/policy-029",
"content-version": "stm-asf",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
2,
1
]
],
"date-time": "2022-02-01T00:00:00Z",
"timestamp": 1643673600000
}
},
{
"URL": "https://doi.org/10.15223/policy-004",
"content-version": "stm-asf",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
2,
1
]
],
"date-time": "2022-02-01T00:00:00Z",
"timestamp": 1643673600000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0925443921002271?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0925443921002271?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "166294",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2022,
2
]
]
},
"published-print": {
"date-parts": [
[
2022,
2
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1038/s41591-020-0820-9",
"article-title": "The proximal origin of SARS-CoV-2",
"author": "Andersen",
"doi-asserted-by": "crossref",
"first-page": "450",
"journal-title": "Nat. Med.",
"key": "10.1016/j.bbadis.2021.166294_bb0010",
"volume": "26",
"year": "2020"
},
{
"DOI": "10.3389/fphar.2020.00836",
"article-title": "Molecular insights into SARS COV-2 interaction with cardiovascular disease: role of RAAS and MAPK signaling",
"author": "Wehbe",
"doi-asserted-by": "crossref",
"journal-title": "Front. Pharmacol.",
"key": "10.1016/j.bbadis.2021.166294_bb0015",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.3390/v12091058",
"article-title": "Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak",
"author": "Low",
"doi-asserted-by": "crossref",
"first-page": "1058",
"journal-title": "Viruses",
"key": "10.1016/j.bbadis.2021.166294_bb0020",
"volume": "12",
"year": "2020"
},
{
"article-title": "COVID-19: a review on the novel coronavirus disease evolution, transmission, detectionControl and Prevention",
"author": "Sharma",
"first-page": "202",
"key": "10.1016/j.bbadis.2021.166294_bb0025",
"volume": "13",
"year": "2021"
},
{
"DOI": "10.1016/j.jmgm.2020.107762",
"article-title": "Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach",
"author": "Bello",
"doi-asserted-by": "crossref",
"journal-title": "J. Mol. Graph. Model.",
"key": "10.1016/j.bbadis.2021.166294_bb0030",
"volume": "101",
"year": "2020"
},
{
"DOI": "10.1007/s00894-020-04600-4",
"article-title": "Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA",
"author": "Bello",
"doi-asserted-by": "crossref",
"journal-title": "J. Mol. Model.",
"key": "10.1016/j.bbadis.2021.166294_bb0035",
"volume": "26",
"year": "2020"
},
{
"DOI": "10.3390/ph14050454",
"article-title": "Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection",
"author": "Zanella",
"doi-asserted-by": "crossref",
"first-page": "454",
"journal-title": "Pharmaceuticals",
"key": "10.1016/j.bbadis.2021.166294_bb0040",
"volume": "14",
"year": "2021"
},
{
"DOI": "10.1128/AAC.00819-20",
"article-title": "Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs",
"author": "Jeon",
"doi-asserted-by": "crossref",
"journal-title": "Antimicrob. Agents Chemother.",
"key": "10.1016/j.bbadis.2021.166294_bb0045",
"volume": "64",
"year": "2020"
},
{
"DOI": "10.1016/j.pt.2017.02.004",
"article-title": "Ivermectin – old drug, new Tricks?",
"author": "Laing",
"doi-asserted-by": "crossref",
"first-page": "463",
"journal-title": "Trends Parasitol.",
"key": "10.1016/j.bbadis.2021.166294_bb0050",
"volume": "33",
"year": "2017"
},
{
"DOI": "10.1016/j.ijantimicag.2007.08.023",
"article-title": "Ivermectin: 25 years and still going strong",
"author": "Õmura",
"doi-asserted-by": "crossref",
"first-page": "91",
"journal-title": "Int. J. Antimicrob. Agents",
"key": "10.1016/j.bbadis.2021.166294_bb0055",
"volume": "31",
"year": "2008"
},
{
"DOI": "10.1126/science.6308762",
"article-title": "Ivermectin: a potent new antiparasitic agent",
"author": "Campbell",
"doi-asserted-by": "crossref",
"first-page": "823",
"journal-title": "Science",
"key": "10.1016/j.bbadis.2021.166294_bb0060",
"volume": "221",
"year": "1983"
},
{
"DOI": "10.1038/nrmicro1048",
"article-title": "The life and times of ivermectin — a success story",
"author": "Õmura",
"doi-asserted-by": "crossref",
"first-page": "984",
"journal-title": "Nat. Rev. Microbiol.",
"key": "10.1016/j.bbadis.2021.166294_bb0065",
"volume": "2",
"year": "2004"
},
{
"DOI": "10.1016/j.ijantimicag.2019.05.003",
"article-title": "Ivermectin: from theory to clinical application",
"author": "Ashour",
"doi-asserted-by": "crossref",
"first-page": "134",
"journal-title": "Int. J. Antimicrob. Agents",
"key": "10.1016/j.bbadis.2021.166294_bb0070",
"volume": "54",
"year": "2019"
},
{
"DOI": "10.1111/j.1365-3156.2004.01211.x",
"article-title": "Review: the delivery of ivermectin (MectizanR)",
"author": "Burnham",
"doi-asserted-by": "crossref",
"first-page": "A26",
"journal-title": "Trop. Med. Int. Health",
"key": "10.1016/j.bbadis.2021.166294_bb0075",
"volume": "9",
"year": "2004"
},
{
"DOI": "10.3390/antibiotics10040381",
"article-title": "Repurposing avermectins and milbemycins against mycobacteroides abscessus and other nontuberculous mycobacteria",
"author": "Muñoz-Muñoz",
"doi-asserted-by": "crossref",
"first-page": "381",
"journal-title": "Antibiotics",
"key": "10.1016/j.bbadis.2021.166294_bb0080",
"volume": "10",
"year": "2021"
},
{
"DOI": "10.1016/j.phrs.2020.105207",
"article-title": "Ivermectin, a potential anticancer drug derived from an antiparasitic drug",
"author": "Tang",
"doi-asserted-by": "crossref",
"journal-title": "Pharmacol. Res.",
"key": "10.1016/j.bbadis.2021.166294_bb0085",
"volume": "163",
"year": "2021"
},
{
"DOI": "10.1093/brain/awv167",
"article-title": "DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis",
"author": "Yin",
"doi-asserted-by": "crossref",
"first-page": "2553",
"journal-title": "Brain",
"key": "10.1016/j.bbadis.2021.166294_bb0090",
"volume": "138",
"year": "2015"
},
{
"DOI": "10.1038/srep17288",
"article-title": "Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease",
"author": "Jin",
"doi-asserted-by": "crossref",
"journal-title": "Sci. Rep.",
"key": "10.1016/j.bbadis.2021.166294_bb0095",
"volume": "5",
"year": "2015"
},
{
"DOI": "10.1093/jac/dks147",
"article-title": "Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug",
"author": "Mastrangelo",
"doi-asserted-by": "crossref",
"first-page": "1884",
"journal-title": "J. Antimicrob. Chemother.",
"key": "10.1016/j.bbadis.2021.166294_bb0100",
"volume": "67",
"year": "2012"
},
{
"DOI": "10.1042/BJ20120150",
"article-title": "Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus",
"author": "Wagstaff",
"doi-asserted-by": "crossref",
"first-page": "851",
"journal-title": "Biochem. J.",
"key": "10.1016/j.bbadis.2021.166294_bb0105",
"volume": "443",
"year": "2012"
},
{
"DOI": "10.1016/j.antiviral.2020.104787",
"article-title": "The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro",
"author": "Caly",
"doi-asserted-by": "crossref",
"journal-title": "Antivir. Res.",
"key": "10.1016/j.bbadis.2021.166294_bb0110",
"volume": "178",
"year": "2020"
},
{
"DOI": "10.3389/fimmu.2021.663586",
"article-title": "Repurposing ivermectin for COVID-19: molecular aspects and therapeutic possibilities",
"author": "Wehbe",
"doi-asserted-by": "crossref",
"journal-title": "Front. Immunol.",
"key": "10.1016/j.bbadis.2021.166294_bb0115",
"volume": "12",
"year": "2021"
},
{
"DOI": "10.1080/00480169.1981.34836",
"article-title": "An introduction to the avermectins",
"author": "Campbell",
"doi-asserted-by": "crossref",
"first-page": "174",
"journal-title": "N. Z. Vet. J.",
"key": "10.1016/j.bbadis.2021.166294_bb0120",
"volume": "29",
"year": "1981"
},
{
"DOI": "10.1007/s43440-020-00195-y",
"article-title": "Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes",
"author": "Kaur",
"doi-asserted-by": "crossref",
"first-page": "736",
"journal-title": "Pharmacol. Rep.",
"key": "10.1016/j.bbadis.2021.166294_bb0125",
"volume": "73",
"year": "2021"
},
{
"DOI": "10.3390/cells9092100",
"article-title": "Ivermectin as a broad-Spectrum host-directed antiviral: the real deal?",
"author": "Jans",
"doi-asserted-by": "crossref",
"first-page": "2100",
"journal-title": "Cells",
"key": "10.1016/j.bbadis.2021.166294_bb0130",
"volume": "9",
"year": "2020"
},
{
"DOI": "10.4269/ajtmh.20-0271",
"article-title": "Ivermectin and COVID-19: keeping rigor in times of urgency",
"author": "Chaccour",
"doi-asserted-by": "crossref",
"first-page": "1156",
"journal-title": "Am. J. Trop. Med. Hyg.",
"key": "10.1016/j.bbadis.2021.166294_bb0135",
"volume": "102",
"year": "2020"
},
{
"DOI": "10.3389/fphar.2020.01196",
"article-title": "COVID-19 therapeutic options under investigation",
"author": "Kaddoura",
"doi-asserted-by": "crossref",
"journal-title": "Front. Pharmacol.",
"key": "10.1016/j.bbadis.2021.166294_bb0140",
"volume": "11",
"year": "2020"
},
{
"DOI": "10.1128/JVI.01012-07",
"article-title": "Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/golgimembrane",
"author": "Frieman",
"doi-asserted-by": "crossref",
"first-page": "9812",
"journal-title": "J. Virol.",
"key": "10.1016/j.bbadis.2021.166294_bb0145",
"volume": "81",
"year": "2007"
},
{
"DOI": "10.3389/fmicb.2015.00553",
"article-title": "Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses",
"author": "Wulan",
"doi-asserted-by": "crossref",
"journal-title": "Front. Microbiol.",
"key": "10.1016/j.bbadis.2021.166294_bb0150",
"volume": "6",
"year": "2015"
},
{
"DOI": "10.1016/j.chom.2016.07.004",
"article-title": "A screen of FDA-approved drugs for inhibitors of zika virus infection",
"author": "Barrows",
"doi-asserted-by": "crossref",
"first-page": "259",
"journal-title": "Cell Host Microbe",
"key": "10.1016/j.bbadis.2021.166294_bb0155",
"volume": "20",
"year": "2016"
},
{
"DOI": "10.1056/NEJMra1602113",
"article-title": "Zika virus",
"author": "Petersen",
"doi-asserted-by": "crossref",
"first-page": "1552",
"journal-title": "N. Engl. J. Med.",
"key": "10.1016/j.bbadis.2021.166294_bb0160",
"volume": "374",
"year": "2016"
},
{
"DOI": "10.1016/j.virol.2019.10.010",
"article-title": "Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication",
"author": "Ji",
"doi-asserted-by": "crossref",
"first-page": "124",
"journal-title": "Virology",
"key": "10.1016/j.bbadis.2021.166294_bb0170",
"volume": "541",
"year": "2020"
},
{
"DOI": "10.1128/CMR.00045-12",
"article-title": "West Nile virus: biology, transmission, and human infection",
"author": "Colpitts",
"doi-asserted-by": "crossref",
"first-page": "635",
"journal-title": "Clin. Microbiol. Rev.",
"key": "10.1016/j.bbadis.2021.166294_bb0175",
"volume": "25",
"year": "2012"
},
{
"DOI": "10.1093/jac/dks147",
"article-title": "Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug",
"author": "Mastrangelo",
"doi-asserted-by": "crossref",
"first-page": "1884",
"journal-title": "J. Antimicrob. Chemother.",
"key": "10.1016/j.bbadis.2021.166294_bb0180",
"volume": "67",
"year": "2012"
},
{
"DOI": "10.1016/j.cell.2009.01.029",
"article-title": "The influenza virus enigma",
"author": "Salomon",
"doi-asserted-by": "crossref",
"first-page": "402",
"journal-title": "Cell",
"key": "10.1016/j.bbadis.2021.166294_bb0185",
"volume": "136",
"year": "2009"
},
{
"article-title": "Influenza a viruses escape from MxA restriction at the expense of efficient nuclear vRNP import",
"author": "Götz",
"journal-title": "Sci. Rep.",
"key": "10.1016/j.bbadis.2021.166294_bb0190",
"volume": "6",
"year": "2016"
},
{
"DOI": "10.1128/JVI.02220-13",
"article-title": "The human interferon-induced MxA protein inhibits early stages of influenza a virus infection by retaining the incoming viral genome in the cytoplasm",
"author": "Xiao",
"doi-asserted-by": "crossref",
"first-page": "13053",
"journal-title": "J. Virol.",
"key": "10.1016/j.bbadis.2021.166294_bb0195",
"volume": "87",
"year": "2013"
},
{
"DOI": "10.1128/JVI.00712-11",
"article-title": "The viral nucleoprotein determines mx sensitivity of influenza a viruses",
"author": "Zimmermann",
"doi-asserted-by": "crossref",
"first-page": "8133",
"journal-title": "J. Virol.",
"key": "10.1016/j.bbadis.2021.166294_bb0200",
"volume": "85",
"year": "2011"
},
{
"DOI": "10.3389/fimmu.2018.01547",
"article-title": "Advancements in host-based interventions for influenza treatment",
"author": "Yip",
"doi-asserted-by": "crossref",
"journal-title": "Front. Immunol.",
"key": "10.1016/j.bbadis.2021.166294_bb0205",
"volume": "9",
"year": "2018"
},
{
"DOI": "10.1021/cb600131q",
"article-title": "Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses",
"author": "Smith",
"doi-asserted-by": "crossref",
"first-page": "217",
"journal-title": "ACS Chem. Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0210",
"volume": "1",
"year": "2006"
},
{
"DOI": "10.1016/j.antiviral.2020.104760",
"article-title": "The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer",
"author": "Yang",
"doi-asserted-by": "crossref",
"journal-title": "Antivir. Res.",
"key": "10.1016/j.bbadis.2021.166294_bb0215",
"volume": "177",
"year": "2020"
},
{
"DOI": "10.1038/s41586-020-2012-7",
"article-title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin",
"author": "Zhou",
"doi-asserted-by": "crossref",
"first-page": "270",
"journal-title": "Nature",
"key": "10.1016/j.bbadis.2021.166294_bb0220",
"volume": "579",
"year": "2020"
},
{
"DOI": "10.1016/j.jare.2020.03.005",
"article-title": "COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses",
"author": "Shereen",
"doi-asserted-by": "crossref",
"first-page": "91",
"journal-title": "J. Adv. Res.",
"key": "10.1016/j.bbadis.2021.166294_bb0225",
"volume": "24",
"year": "2020"
},
{
"DOI": "10.1016/j.bbadis.2020.165878",
"article-title": "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach",
"author": "Naqvi",
"doi-asserted-by": "crossref",
"journal-title": "Biochim. Biophys. Acta (BBA) - Mol. Basis Dis.",
"key": "10.1016/j.bbadis.2021.166294_bb0230",
"volume": "1866",
"year": "2020"
},
{
"article-title": "Coronaviruses: an overview of their replication and pathogenesis",
"author": "Fehr",
"first-page": "1",
"journal-title": "Coronaviruses",
"key": "10.1016/j.bbadis.2021.166294_bb0235",
"year": "2015"
},
{
"DOI": "10.1128/JVI.00645-06",
"article-title": "Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy",
"author": "Neuman",
"doi-asserted-by": "crossref",
"first-page": "7918",
"journal-title": "J. Virol.",
"key": "10.1016/j.bbadis.2021.166294_bb0240",
"volume": "80",
"year": "2006"
},
{
"article-title": "Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin",
"author": "Sen Gupta",
"first-page": "1",
"journal-title": "J. Biomol. Struct. Dyn.",
"key": "10.1016/j.bbadis.2021.166294_bb0245",
"year": "2020"
},
{
"DOI": "10.1128/JVI.01012-07",
"article-title": "Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic Reticulum/Golgi membrane",
"author": "Frieman",
"doi-asserted-by": "crossref",
"first-page": "9812",
"journal-title": "J. Virol.",
"key": "10.1016/j.bbadis.2021.166294_bb0250",
"volume": "81",
"year": "2007"
},
{
"DOI": "10.1016/j.ejmech.2021.113201",
"article-title": "RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic",
"author": "Tian",
"doi-asserted-by": "crossref",
"journal-title": "Eur. J. Med. Chem.",
"key": "10.1016/j.bbadis.2021.166294_bb0255",
"volume": "213",
"year": "2021"
},
{
"article-title": "The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2",
"author": "Saha",
"first-page": "1",
"journal-title": "Struct. Chem.",
"key": "10.1016/j.bbadis.2021.166294_bb0260",
"year": "2021"
},
{
"DOI": "10.1038/s42003-020-01577-x",
"article-title": "Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents",
"author": "Mody",
"doi-asserted-by": "crossref",
"journal-title": "Commun. Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0265",
"volume": "4",
"year": "2021"
},
{
"DOI": "10.1016/j.ceb.2019.01.001",
"article-title": "Inhibitors of nuclear transport",
"author": "Jans",
"doi-asserted-by": "crossref",
"first-page": "50",
"journal-title": "Curr. Opin. Cell Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0270",
"volume": "58",
"year": "2019"
},
{
"DOI": "10.1016/j.antiviral.2012.06.008",
"article-title": "Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?",
"author": "Caly",
"doi-asserted-by": "crossref",
"first-page": "202",
"journal-title": "Antivir. Res.",
"key": "10.1016/j.bbadis.2021.166294_bb0275",
"volume": "95",
"year": "2012"
},
{
"DOI": "10.3390/cells8030281",
"article-title": "Novel flavivirus antiviral that targets the host nuclear transport importin α/β1 heterodimer",
"author": "Yang",
"doi-asserted-by": "crossref",
"first-page": "281",
"journal-title": "Cells",
"key": "10.1016/j.bbadis.2021.166294_bb0280",
"volume": "8",
"year": "2019"
},
{
"key": "10.1016/j.bbadis.2021.166294_bb0285",
"unstructured": "Waheed Shouman . Prophylactic Ivermectin in COVID-19 Contacts - Study Results - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT04422561 (Accessed Jun 10, 2021)."
},
{
"article-title": "Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies",
"author": "Hariyanto",
"journal-title": "Rev. Med. Virol.",
"key": "10.1016/j.bbadis.2021.166294_bb0290",
"year": "2021"
},
{
"author": "Swargiary",
"key": "10.1016/j.bbadis.2021.166294_bb0295",
"series-title": "Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies",
"year": "2020"
},
{
"DOI": "10.1038/s41418-020-00633-7",
"article-title": "An aberrant STAT pathway is central to COVID-19",
"author": "Matsuyama",
"doi-asserted-by": "crossref",
"first-page": "3209",
"journal-title": "Cell Death Differ.",
"key": "10.1016/j.bbadis.2021.166294_bb0300",
"volume": "27",
"year": "2020"
},
{
"DOI": "10.1016/j.chom.2020.05.008",
"article-title": "Type I and type III interferons – induction, signaling, evasion, and application to combat COVID-19",
"author": "Park",
"doi-asserted-by": "crossref",
"first-page": "870",
"journal-title": "Cell Host Microbe",
"key": "10.1016/j.bbadis.2021.166294_bb0305",
"volume": "27",
"year": "2020"
},
{
"DOI": "10.1074/jbc.M116.745729",
"article-title": "Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-α1 degradation",
"author": "Wang",
"doi-asserted-by": "crossref",
"first-page": "10262",
"journal-title": "J. Biol. Chem.",
"key": "10.1016/j.bbadis.2021.166294_bb0310",
"volume": "292",
"year": "2017"
},
{
"DOI": "10.3390/ijms20194870",
"article-title": "STAT3 regulates the type I IFN-mediated antiviral response by interfering with the nuclear entry of STAT1",
"author": "Wang",
"doi-asserted-by": "crossref",
"first-page": "4870",
"journal-title": "Int. J. Mol. Sci.",
"key": "10.1016/j.bbadis.2021.166294_bb0315",
"volume": "20",
"year": "2019"
},
{
"DOI": "10.1165/rcmb.2012-0100TR",
"article-title": "Human epidermal growth factor receptor signaling in acute lung injury",
"author": "Finigan",
"doi-asserted-by": "crossref",
"first-page": "395",
"journal-title": "Am. J. Respir. Cell Mol. Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0320",
"volume": "47",
"year": "2012"
},
{
"DOI": "10.1016/j.bbrc.2016.06.065",
"article-title": "Plasminogen activator inhibitor-1 stimulates macrophage activation through toll-like Receptor-4",
"author": "Gupta",
"doi-asserted-by": "crossref",
"first-page": "503",
"journal-title": "Biochem. Biophys. Res. Commun.",
"key": "10.1016/j.bbadis.2021.166294_bb0325",
"volume": "477",
"year": "2016"
},
{
"DOI": "10.1165/rcmb.2008-0003ED",
"article-title": "What the lung has taught us about latent TGF-β activation",
"author": "Aluwihare",
"doi-asserted-by": "crossref",
"first-page": "499",
"journal-title": "Am. J. Respir. Cell Mol. Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0330",
"volume": "39",
"year": "2008"
},
{
"DOI": "10.4049/jimmunol.1402513",
"article-title": "The acute respiratory distress syndrome: from mechanism to translation",
"author": "Han",
"doi-asserted-by": "crossref",
"first-page": "855",
"journal-title": "J. Immunol.",
"key": "10.1016/j.bbadis.2021.166294_bb0335",
"volume": "194",
"year": "2015"
},
{
"DOI": "10.1158/0008-5472.CAN-15-2887",
"article-title": "Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt Axis in breast cancer",
"author": "Dou",
"doi-asserted-by": "crossref",
"first-page": "4457",
"journal-title": "Cancer Res.",
"key": "10.1016/j.bbadis.2021.166294_bb0340",
"volume": "76",
"year": "2016"
},
{
"DOI": "10.3390/ijms22041737",
"article-title": "Understanding viral infection mechanisms and patient symptoms for the development of COVID-19 therapeutics",
"author": "Choi",
"doi-asserted-by": "crossref",
"first-page": "1737",
"journal-title": "Int. J. Mol. Sci.",
"key": "10.1016/j.bbadis.2021.166294_bb0345",
"volume": "22",
"year": "2021"
},
{
"DOI": "10.1038/s41423-020-0458-z",
"article-title": "Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies",
"author": "Yi",
"doi-asserted-by": "crossref",
"first-page": "621",
"journal-title": "Cell. Mol. Immunol.",
"key": "10.1016/j.bbadis.2021.166294_bb0350",
"volume": "17",
"year": "2020"
},
{
"DOI": "10.1016/j.gene.2020.145325",
"article-title": "The potential involvement of JAK-STAT signalling pathway in the COVID-19 infection assisted by ACE2",
"author": "Luo",
"doi-asserted-by": "crossref",
"journal-title": "Gene",
"key": "10.1016/j.bbadis.2021.166294_bb0355",
"volume": "768",
"year": "2021"
},
{
"author": "Hennighausen",
"key": "10.1016/j.bbadis.2021.166294_bb0360",
"series-title": "Activation of the SARS-CoV-2 receptorAce2by cytokines through pan JAK-STAT enhancers",
"year": "2020"
},
{
"DOI": "10.2217/fvl-2020-0342",
"article-title": "Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in-silico approach",
"author": "Choudhury",
"doi-asserted-by": "crossref",
"first-page": "277",
"journal-title": "Futur. Virol.",
"key": "10.1016/j.bbadis.2021.166294_bb0365",
"volume": "16",
"year": "2021"
},
{
"DOI": "10.21873/invivo.12134",
"article-title": "Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2",
"author": "Lehrer",
"doi-asserted-by": "crossref",
"first-page": "3023",
"journal-title": "In Vivo",
"key": "10.1016/j.bbadis.2021.166294_bb0370",
"volume": "34",
"year": "2020"
},
{
"article-title": "Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets",
"author": "Bello",
"first-page": "1",
"journal-title": "J. Biomol. Struct. Dyn.",
"key": "10.1016/j.bbadis.2021.166294_bb0375",
"year": "2021"
},
{
"DOI": "10.1038/s41598-021-88630-9",
"article-title": "The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors",
"author": "Silvestrini",
"doi-asserted-by": "crossref",
"journal-title": "Sci. Rep.",
"key": "10.1016/j.bbadis.2021.166294_bb0380",
"volume": "11",
"year": "2021"
},
{
"DOI": "10.1016/j.jmgm.2020.107762",
"article-title": "Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach",
"author": "Bello",
"doi-asserted-by": "crossref",
"journal-title": "J. Mol. Graph. Model.",
"key": "10.1016/j.bbadis.2021.166294_bb0385",
"volume": "101",
"year": "2020"
},
{
"DOI": "10.1126/science.abb3405",
"article-title": "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors",
"author": "Zhang",
"doi-asserted-by": "crossref",
"first-page": "409",
"journal-title": "Science",
"key": "10.1016/j.bbadis.2021.166294_bb0390",
"volume": "368",
"year": "2020"
},
{
"DOI": "10.1038/s41586-020-2223-y",
"article-title": "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors",
"author": "Jin",
"doi-asserted-by": "crossref",
"first-page": "289",
"journal-title": "Nature",
"key": "10.1016/j.bbadis.2021.166294_bb0395",
"volume": "582",
"year": "2020"
},
{
"DOI": "10.1107/S2053230X20011814",
"article-title": "Room-temperature neutron and X-ray data collection of 3CL mprofrom SARS-CoV-2",
"author": "Kneller",
"doi-asserted-by": "crossref",
"first-page": "483",
"journal-title": "Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.",
"key": "10.1016/j.bbadis.2021.166294_bb0400",
"volume": "76",
"year": "2020"
},
{
"article-title": "Design of wide-spectrum inhibitors targeting coronavirus main proteases",
"author": "Yang",
"journal-title": "PLoS Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0405",
"volume": "3",
"year": "2005"
},
{
"DOI": "10.1126/science.abb4489",
"article-title": "Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease",
"author": "Dai",
"doi-asserted-by": "crossref",
"first-page": "1331",
"journal-title": "Science",
"key": "10.1016/j.bbadis.2021.166294_bb0410",
"volume": "368",
"year": "2020"
},
{
"DOI": "10.1016/j.jtbi.2008.07.030",
"article-title": "Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors",
"author": "Nukoolkarn",
"doi-asserted-by": "crossref",
"first-page": "861",
"journal-title": "J. Theor. Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0415",
"volume": "254",
"year": "2008"
},
{
"DOI": "10.1016/j.antiviral.2020.104786",
"article-title": "Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro",
"author": "Choy",
"doi-asserted-by": "crossref",
"journal-title": "Antivir. Res.",
"key": "10.1016/j.bbadis.2021.166294_bb0420",
"volume": "178",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2001282",
"article-title": "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19",
"author": "Cao",
"doi-asserted-by": "crossref",
"first-page": "1787",
"journal-title": "N. Engl. J. Med.",
"key": "10.1016/j.bbadis.2021.166294_bb0425",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.3389/fmolb.2020.616341",
"article-title": "Recent Progress in the drug development targeting SARS-CoV-2 Main protease as treatment for COVID-19",
"author": "Cui",
"doi-asserted-by": "crossref",
"journal-title": "Front. Mol. Biosci.",
"key": "10.1016/j.bbadis.2021.166294_bb0430",
"volume": "7",
"year": "2020"
},
{
"DOI": "10.1126/science.1085658",
"article-title": "Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs",
"author": "Anand",
"doi-asserted-by": "crossref",
"first-page": "1763",
"journal-title": "Science",
"key": "10.1016/j.bbadis.2021.166294_bb0435",
"volume": "300",
"year": "2003"
},
{
"DOI": "10.1016/j.jtbi.2008.07.030",
"article-title": "Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors",
"author": "Nukoolkarn",
"doi-asserted-by": "crossref",
"first-page": "861",
"journal-title": "J. Theor. Biol.",
"key": "10.1016/j.bbadis.2021.166294_bb0440",
"volume": "254",
"year": "2008"
},
{
"DOI": "10.1080/1061186X.2020.1853736",
"article-title": "Potential inhibitors of SARS-CoV-2: recent advances",
"author": "Jamalipour Soufi",
"doi-asserted-by": "crossref",
"first-page": "349",
"journal-title": "J. Drug Target.",
"key": "10.1016/j.bbadis.2021.166294_bb0445",
"volume": "29",
"year": "2020"
},
{
"DOI": "10.3390/v13060989",
"article-title": "Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon",
"author": "Samaha",
"doi-asserted-by": "crossref",
"first-page": "989",
"journal-title": "Viruses",
"key": "10.1016/j.bbadis.2021.166294_bb0450",
"volume": "13",
"year": "2021"
},
{
"DOI": "10.1016/S1473-3099(20)30883-5",
"article-title": "Ct values and infectivity of SARS-CoV-2 on surfaces",
"author": "Kampf",
"doi-asserted-by": "crossref",
"journal-title": "Lancet Infect. Dis.",
"key": "10.1016/j.bbadis.2021.166294_bb0455",
"volume": "21",
"year": "2021"
},
{
"DOI": "10.1097/MJT.0000000000001377",
"article-title": "Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19",
"author": "Kory",
"doi-asserted-by": "crossref",
"first-page": "e299",
"journal-title": "Am. J. Ther.",
"key": "10.1016/j.bbadis.2021.166294_bb0460",
"volume": "28",
"year": "2021"
},
{
"author": "Elgazzar",
"key": "10.1016/j.bbadis.2021.166294_bb0465",
"series-title": "Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic",
"year": "2020"
},
{
"DOI": "10.31546/2633-8653.1007",
"article-title": "Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel",
"author": "Héctor",
"doi-asserted-by": "crossref",
"journal-title": "J. Biomed. Res. Clin. Investig.",
"key": "10.1016/j.bbadis.2021.166294_bb0470",
"volume": "2",
"year": "2020"
},
{
"DOI": "10.1371/journal.pone.0242184",
"article-title": "Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients",
"author": "Camprubí",
"doi-asserted-by": "crossref",
"journal-title": "PLOS ONE",
"key": "10.1016/j.bbadis.2021.166294_bb0475",
"volume": "15",
"year": "2020"
},
{
"DOI": "10.1016/j.eclinm.2021.100959",
"article-title": "Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial",
"author": "Krolewiecki",
"doi-asserted-by": "crossref",
"journal-title": "EClinicalMedicine",
"key": "10.1016/j.bbadis.2021.166294_bb0480",
"volume": "37",
"year": "2021"
},
{
"DOI": "10.1001/jama.2021.3071",
"article-title": "Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19",
"author": "López-Medina",
"doi-asserted-by": "crossref",
"first-page": "1426",
"journal-title": "JAMA",
"key": "10.1016/j.bbadis.2021.166294_bb0485",
"volume": "325",
"year": "2021"
},
{
"DOI": "10.1016/j.eclinm.2021.100744",
"article-title": "Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?",
"author": "Ramírez",
"doi-asserted-by": "crossref",
"journal-title": "EClinicalMedicine",
"key": "10.1016/j.bbadis.2021.166294_bb0490",
"volume": "32",
"year": "2021"
},
{
"DOI": "10.1002/cpt.1889",
"article-title": "The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19",
"author": "Schmith",
"doi-asserted-by": "crossref",
"first-page": "762",
"journal-title": "Clin. Pharmacol. Ther.",
"key": "10.1016/j.bbadis.2021.166294_bb0495",
"volume": "108",
"year": "2020"
}
],
"reference-count": 97,
"references-count": 97,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0925443921002271"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy",
"volume": "1868"
}
